Macie L. Champion

Macie L. Champion

Auto-generated profile, based on publicly available information

Macie L. Champion

Division of Maternal-Fetal Medicine, Department of OBGYN, University of Alabama at Birmingham, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
MCMacie L. Champion
Macie L. Champion
LHLorie M. Harper
Lorie M. Harper

7 March 2022 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
MCMacie L. Champion
Macie L. Champion
ABAshley N. Battarbee
Ashley N. Battarbee
JBJoseph R. Biggio
Joseph R. Biggio
BCBrian M. Casey
Brian M. Casey
LHLorie M. Harper
Lorie M. Harper

23 July 2024 in JAMA
Verified
Journal Article
Closed access
PDF file
MCMacie L. Champion
Macie L. Champion
CBChristina T. Blanchard
Christina T. Blanchard
MLMichelle Y. Lu
Michelle Y. Lu
ASAshley E. Shea
Ashley E. Shea
ALAnna I. Lively
Anna I. Lively
ASAkila Subramaniam
Akila Subramaniam
Importance: In 2016, our institution adopted a pregnancy-related venous thromboembolism (VTE) prophylaxis protocol based on American College of Obstetricians and Gynecologists guidelines that recommended postpartum heparin-based chemoprophylaxis (enoxaparin) based on a risk-stratified algorithm. In response to increased wound hematomas without significant reduction in VTE using this protocol, a more selective risk-stratified approach was adopted in 2021.Objective: To evaluate outcomes of the more selective risk-stratified approach to heparin-based obstetric thromboprophylaxis (enoxaparin) protocol.Design, Setting, and Participants: Retrospective observational study of 17 489 patients who delivered at a single tertiary care center in the southeast US between January 1, 2016, and December 31, 2018 (original protocol), and between December 1, 2021, and May 31, 2023 (more selective protocol). Patients receiving outpatient anticoagulation for active VTE or high VTE risk during pregnancy were excluded.Exposure: Standard risk-stratified and more selective postpartum VTE chemoprophylaxis protocols.Main Outcomes and Measures: The primary outcome was clinical diagnosis of wound hematoma up to 6 weeks pos tpartum. The secondary outcome was new diagnosis of VTE up to 6 weeks post partum. We compared baseline characteristics and outcomes between groups and estimated adjusted odds ratios with 95% CIs of primary and secondary outcomes using the original protocol group as reference.Results: Of 17 489 patients included in the analysis, 12 430 (71%) were in the original protocol group and 5029 (29%) were in the more selective group. Rates of chemoprophylaxis decreased from 16% (original protocol) to 8% (more selective protocol). Patients in the more selective group were more likely to be older, be married, and have obesity or other comorbidities (hypertension, diabetes, cardiac disease). Compared with the original protocol, the more selective protocol was associated with a decrease in any wound hematoma (0.7% vs 0.3%; adjusted odds ratio [aOR], 0.38; 95% CI, 0.21-0.67), specifically due to a lower rate of superficial wound hematomas (0.6% vs 0.3%; aOR, 0.43; 95% CI, 0.24-0.75). There was no significant increase in VTE or individual types of VTE (0.1% vs 0.1%; aOR, 0.40; 95% CI, 0.12-1.36).Conclusions and Relevance: A more selective risk-stratified approach to an enoxaparin thromboprophylaxis protocol for VTE was associated with decreased rates of wound hematomas without increased rates of postpartum VTE.

16 August 2022 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MCMacie L. Champion
Macie L. Champion
VJVictoria C. Jauk
Victoria C. Jauk
JBJoseph R. Biggio
Joseph R. Biggio
JSJeff M. Sychowski
Jeff M. Sychowski
ATAlan T. Tita
Alan T. Tita
LHLorie M. Harper
Lorie M. Harper
Objective A recent randomized controlled trial suggested that early gestational diabetes mellitus (GDM) screening in patients with obesity (body mass index [BMI] ≥30 kg/m2) does not improve perinatal outcomes. The American College of Obstetrics and Gynecology currently recommends early screening for gestational diabetes in patients who are overweight with one or more additional risk factors. We evaluated the effect of screening based on the number of additional risk factors for development of gestational diabetes. Study Design This was a secondary analysis of a multicenter randomized controlled trial of obese patients with singleton nonanomalous fetuses comparing early (14–20 weeks' gestation) with routine (24–28 weeks' gestation) GDM screening. Exclusion criteria were pregestational diabetes, major medical illnesses, bariatric surgery, chronic steroid use, and prior cesarean. Early versus routine GDM screening groups were compared and stratified by the number of additional risk factors for GDM (0, 1, 2, and ≥3). The primary outcome was an adverse perinatal composite outcome composed of: macrosomia, primary cesarean delivery, hypertensive disorders of pregnancy, shoulder dystocia, neonatal hyperbilirubinemia, and neonatal hypoglycemia. Analyses examined effects of early versus routine screening by the number of additional risk factors and their possible interaction on the incidences of the primary outcome and GDM. Results Of 913 patients, 5% had 0, 52% had 1, 33% had 2, and 10% had ≥3 additional risk factors. Baseline characteristics, including the number and type of risk factors, were similar between early and routine screening groups. Breslow–Day test for interaction between early versus routine screening and the number of additional risk factors was not significant for either the primary outcome (p = 0.37) or the diagnosis of GDM (p = 0.28). The incidence of GDM and the adverse perinatal composite outcome increased as the number of risk factors increased (p < 0.001). Conclusion In patients with BMI ≥30 kg/m2 and additional risk factors, early GDM screening does not prevent adverse outcomes. Key Points

11 July 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
MCMacie L. Champion
Macie L. Champion
RSRobin Steele
Robin Steele
RSRachel Sinkey
Rachel Sinkey
ATAlan T. Tita
Alan T. Tita
LHLorie M. Harper
Lorie M. Harper
To examine the relationship between baseline renal function (serum creatinine, urine protein to creatinine ratio) in women with diabetes and adverse pregnancy outcomes.This was a retrospective coho...

10 March 2023 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MCMacie L. Champion
Macie L. Champion
JMJulia G. Maier
Julia G. Maier
EBElisa Thelys Bushman
Elisa Thelys Bushman
JBJoseph B. Barney
Joseph B. Barney
BCBrian M. Casey
Brian M. Casey
RSRachel G. Sinkey
Rachel G. Sinkey
Objective Lymphangioleiomyomatosis (LAM) is a rare, multisystem disease that primarily affects women of reproductive age. Disease progression has been linked to estrogen exposure, and as such many patients are advised to avoid pregnancy. Data are limited regarding the interaction between LAM and pregnancy, and as such we performed a systematic review to summarize available literature reporting outcomes of pregnancies complicated by maternal LAM. Study Design This was a systematic review including randomized controlled trials, observational studies, systematic reviews, case reports, clinical practice guidelines, and quality improvement studies with full-text manuscripts or abstracts in the English language with primary data on pregnant or postpartum patients with LAM. The primary outcome was maternal outcomes during pregnancy as well as pregnancy outcomes. Secondary outcomes were neonatal outcomes and long-term maternal outcomes. This search occurred in July 2020 and included MEDLINE, Scopus, clinicaltrials.gov, Embase, and Cochrane Central. Risk of bias was ascertained using the Newcastle–Ottawa Scale. Our systematic review was registered with PROSPERO as protocol number CRD 42020191402. Results A total of 175 publications were identified in our initial search; ultimately 31 studies were included. Six (19%) studies were retrospective cohort studies and 25 (81%) studies were case reports. Patients diagnosed during pregnancy had worse pregnancy outcomes compared to those diagnosed with LAM prior to pregnancy. Multiple studies reported a significant risk of pneumothoraces during pregnancy. Other significant risks included preterm delivery, chylothoraces, and pulmonary function deterioration. A proposed strategy for preconception counseling and antenatal management is provided. Conclusion Patients diagnosed with LAM during pregnancy generally experience worse outcomes including recurrent pneumothoraces and preterm delivery as compared to patients with a LAM diagnosis prior to pregnancy. Given that there are limited studies available, and that the majority are low-quality evidence and subject to bias, further investigation of the interaction between LAM and pregnancy is warranted to guide patient care and counseling. Key Points